STAT+: BeOne wins FDA approval in lymphoma race

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Biotech’s cell therapy boom keeps expanding beyond cancer: CREATE Medicines just raised $122 million to advance its in vivo CAR-T for autoimmune disease into the clinic.

Meanwhile, the Trump administration is searching for a new FDA commissioner, setting up a politically fraught fight over the agency’s future direction.

Continue to STAT+ to read the full story…